文献速递慢性肾脏病肾小球疾病

糖尿病肾病白蛋白尿与非白蛋白尿患者近端小管损伤、炎症和纤维化尿液生物标志物评估

Evaluation of Urinary Biomarkers of Proximal Tubular Injury, Inflammation, and Fibrosis in Patients With Albuminuric and Nonalbuminuric Diabetic Kidney Disease.
PubMed 文献 · Kidney Int Rep · 2021-02-02

本研究在400例糖尿病患者中基线检测9种尿液生物标志物,分析其与慢性肾脏病及进展的关联。结果显示在所有白蛋白尿水平下,白蛋白、RBP和MCP1与CKD进展显著相关;在无白蛋白尿患者中,炎症细胞因子、NGAL和MCP1与进展相关;NAG与eGFR<60 ml/min显著相关。

要点

  • 所有白蛋白尿水平下,ACR、RBP和MCP1与CKD进展显著相关。
  • 无白蛋白尿患者中,MCP1、IL-6和NGAL与进展至CKD 3/4期相关。
  • ACR<3队列中,仅NAG与eGFR<60 ml/min显著相关。

核心结论

  • 在糖尿病患者中,白蛋白、RBP和MCP1在所有白蛋白尿水平均与CKD进展显著相关。
  • 在无白蛋白尿患者中,炎症细胞因子、NGAL和MCP1与CKD进展相关。
  • 在ACR<3队列中,NAG与eGFR<60 ml/min显著相关。

研究设计与样本

  • 研究为在400例糖尿病患者中基线检测9种尿液生物标志物的研究。
  • 采用相关性分析及多因素logistic和线性回归分析评估生物标志物与CKD及进展的关联。

主要发现

  • 在ACR<3队列中,仅NAG与eGFR<60 ml/min显著相关。
  • 在ACR<3队列中,ACR与MCP1联合与2期CKD显著相关。
  • 在所有白蛋白尿水平患者中,ACR、RBP和MCP1与进展相关。
  • 在ACR<3队列中,包含MCP1、IL-6和NGAL的模型与进展至CKD 3/4期显著相关。
  • 线性混合模型显示MCP1、RBP和ACR与进展至3期或更差显著相关,而ACR<3队列中仅MCP1显著。

临床怎么用

  • 尿液ACR、RBP和MCP1或可用于评估糖尿病患者CKD进展风险。
  • 对无白蛋白尿的糖尿病患者,可关注MCP1、IL-6和NGAL以评估进展风险。
  • NAG可能有助于识别ACR<3但eGFR<60 ml/min的患者。

局限性

  • 本研究仅单次基线测量尿液生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Albuminuric and nonalbuminuric pathways contribute to diabetic kidney disease. Proximal tubule and inflammation play important roles in these processes. Urinary biomarker(s) to detect early kidney damage and predict progression are needed. METHODS: Nine urinary biomarkers were measured at baseline in 400 patients with diabetes. Correlation and multivariate logistic and linear regression analyses were performed to assess the association of biomarkers with chronic kidney disease and progression. RESULTS: In the albumin/creatinine ratio (ACR) <3 cohort, the only biomarker significantly associated with estimated glomerular filtration rate < 60 ml/min was N-acetyl-β-d-glucosaminidase. A combination of ACR and monocyte chemoattractant protein 1 (MCP1) were significantly associated with stage 2 chronic kidney disease in this cohort. Logistic models showed that in patients with all levels of albuminuria, ACR, retinol binding protein (RBP), and MCP1 were associated with progression. A model including MCP1, interleukin 6, and neutrophil gelatinase-associated lipocalin showed significant association with progression to chronic kidney disease 3/4 in the ACR <3 cohort. Linear mixed-model regression analyses demonstrated MCP1, RBP, and ACR as significant proteins associated with progression to stage 3 or worse, whereas MCP1 was the only significant biomarker in the ACR <3 cohort. Time-to-event and Cox proportional hazard models confirmed significant hazard ratios for progression for ACR, RBP, and MCP1, with significant differences noted between quantiles of biomarkers for ACR, RBP, and MCP1. CONCLUSION: In this study of diabetic patients with single baseline measurements of urinary biomarkers, albumin, RBP, and MCP1 were significantly associated with chronic kidney disease progression at all levels of albuminuria. Inflammatory cytokines, neutrophil gelatinase-associated lipocalin, and MCP1 were associated with progression in patients without albuminuria. N-acetyl-β-d-glucosaminidase demonstrated a significant association with an estimated glomerular filtration rate < 60 ml/min in the ACR <3 cohort.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Phanish MK, Chapman AN, Yates S, et al. Evaluation of Urinary Biomarkers of Proximal Tubular Injury, Inflammation, and Fibrosis in Patients With Albuminuric and Nonalbuminuric Diabetic Kidney Disease. Kidney Int Rep. 2021. PMID: 34013114. doi:10.1016/j.ekir.2021.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。